Safety and efficacy of new dual endothelin receptor antagonist aprocitentan in resistant hypertension: a systematic review and meta-analysis

被引：0
|
作者：
Azmi, Yusuf [1 ]
Widyantoro, Bambang [2 ]
机构：
[1] Univ Airlangga, Dr Soetomo Gen Hosp, Dept Cardiol & Vasc Med, Fac Med, Surabaya, Indonesia
[2] Univ Indonesia, Natl Cardiovasc Ctr Harapan Kita, Dept Cardiol & Vasc Med, Jakarta, Indonesia
来源：
CLINICAL SCIENCE | 2024年 / 138卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页数：107
相关论文
共 50 条
  • [1] New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis
    Mahfooz, Kamran
    Najeed, Syed
    Tun, Han Naung
    Khamosh, Madina
    Grewal, Daisy
    Hussain, Aftab
    Ong, Kenneth
    Dharmarajan, Lekshmi
    Vasavada, Advait
    [J]. CURRENT PROBLEMS IN CARDIOLOGY, 2023, 48 (07)
  • [2] Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension
    Danaietash, P.
    Verweij, P.
    Flamion, B.
    Menard, J.
    Bellet, M.
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 : 6 - 6
  • [3] Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension
    McCoy, Emily K.
    Lisenby, Katelin M.
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 77 (06) : 699 - 766
  • [4] Aprocitentan Dual endothelin ETA/ETB receptor antagonist Treatment of resistant hypertension
    Warden, B. A.
    Duell, P. B.
    [J]. DRUGS OF THE FUTURE, 2021, 46 (08) : 595 - 611
  • [5] Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
    Angeli, Fabio
    Verdecchia, Paolo
    Reboldi, Gianpaolo
    [J]. CARDIOLOGY AND THERAPY, 2021, 10 (02) : 397 - 406
  • [6] Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
    Fabio Angeli
    Paolo Verdecchia
    Gianpaolo Reboldi
    [J]. Cardiology and Therapy, 2021, 10 : 397 - 406
  • [7] Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension
    Brussee, Janneke M.
    Sidharta, Patricia N.
    Dingemanse, Jasper
    Krause, Andreas
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2024, 51 (03) : 243 - 252
  • [8] Efficacy and safety of renal denervation for resistant hypertension: A systematic review and meta-analysis
    赵丹
    王晓庆
    刘敏
    胡云科
    王沛坚
    周鹏
    [J]. South China Journal of Cardiology, 2020, 21 (03) : 204 - 215
  • [9] Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension
    Verweij, Pierre
    Danaietash, Parisa
    Flamion, Bruno
    Menard, Joel
    Bellet, Marc
    [J]. HYPERTENSION, 2020, 75 (04) : 956 - 965
  • [10] A SYSTEMATIC REVIEW AND META-ANALYSIS OF EFFICACY AND SAFETY OF MINERALOCORTICOID RECEPTOR ANTAGONIST FOR THE TREATMENT OF LOW-RENIN HYPERTENSION
    Shah, Sonali
    Zhang, Jinghong
    Gwini, Stella May
    Young, Morag J.
    Fuller, Peter J.
    Yang, Jun
    [J]. JOURNAL OF HUMAN HYPERTENSION, 2023, 37 : 17 - 17
12345